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Abstract We have investigated protein-protein interaction
between distinct domains of the human CD45 cytoplasmic region
using a yeast two-hybrid system. Consequently, we have found
that the spacer region between two tandem PTP domains
specifically interacts with the membrane-distal PTP domain
(D2). This interaction is mediated by a stretch of amino acid
residues in the carboxyl-terminal half of the spacer region.
Although the membrane proximal region does not directly
interact with either of the two PTP domains, it appears to
function in stabilizing the interaction between the spacer region
and D2. We also demonstrate that the interaction between the
spacer region and D2 might take place intramolecularly.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
CD45 is a transmembrane protein tyrosine phosphatase
(PTP) expressed exclusively in nucleated hematopoietic cells,
and composed of three distinct portions, a variable extracel-
lular domain, a single transmembrane domain and a large
cytoplasmic region containing two tandem PTP domains [1^
3]. So far p56Lck, p56Lyn and p59Fyn have been identi¢ed as
physiological substrates of CD45, and these Src-family kinases
are activated by CD45 through dephosphorylation at their
negative regulatory tyrosine residue [4^10]. Thus, CD45 is
assumed to serve as a positive regulator of these key kinases,
thereby playing an essential role in the immediate early steps
of antigen stimulated signal transduction in T- and B-cells.
However, recent investigation has also suggested that CD45
negatively regulated Src-family kinases through dephosphor-
ylation at the positive regulatory tyrosine residue [11,12].
These apparent opposite roles of CD45 may in part be ex-
plained by dynamic redistribution of CD45 in the plasma
membranes, which would cause inclusion or exclusion of
CD45 from a site of receptor engagement [13,14].
In contrast to the well-established physiological roles of
CD45, little is known about the mechanisms by which the
PTP activity in the cytoplasmic region is regulated. In this
context it should be noted that most transmembrane PTPs,
including CD45, have two tandem PTP domains in their cy-
toplasmic region. Interestingly, only the ¢rst PTP domain
(D1) appeared to contribute to the intrinsic PTP activity of
CD45 and little or no PTP activity has been observed with the
second PTP domain (D2) [15,16]. However, expression of D1
alone in the absence or truncation of D2 resulted in very low
or almost no PTP activity [16]. Thus, both D1 and D2 are
necessary for expressing full PTP activity although D1 seems
to be principally responsible for PTP activity while the exact
role of D2 remains unclear. Contradictory to these observa-
tions, recently Felberg and Johnson reported that D1 alone
expressed in Escherichia coli had substantial PTP activity
although the stability and activity of D1 alone were 2^3
fold less than those of D1-D2 [17].
The sequence homology of D2 is less conserved than that of
D1 between di¡erent transmembrane PTPs, and in some cases
the key residues for PTP activity are missing in D2 [2]. These
observations, together with the fact that no PTP activity has
been detected with D2, suggest that D2 is not an active PTP
but might play a regulatory role for D1. In this context, the
most plausible possibility may be that D2 is involved in de-
termination of substrate speci¢city [15]. Recently Kashio et al.
reported that the D2 domain has an essential role in interac-
tion with the j-chain of T-cell antigen receptor complex
(TCR), by which e⁄cient signals are transmitted to the down-
stream pathway via ZAP-70 [18].
As an attractive possibility for regulatory mechanisms of
PTP activity, recent experiments suggest that CD45 might
form a homodimer, which modulates its PTP activity. This
hypothesis is based on the observation that signal transmis-
sion elicited by a chimera protein consisted of extracellular
and transmembrane domains of epidermal growth factor re-
ceptor (EGF-R), and the cytoplasmic domain of CD45 was
modulated by addition of EGF through possible dimerization
of the chimera protein [19]. In addition, the hypothesis is
strengthened by the crystal structure of a related PTP,
PTPK, in which two molecules form a stable dimer by mutu-
ally protruding the membrane proximal wedge structure to the
catalytic cleft of the opposite molecule [20]. Supporting this
hypothesis, recently Felberg and Johnson reported that D1 of
murine CD45 can form a homodimer in vitro [17]. In contrast
to these observations, D1 of PTPW and D1-D2 of LAR have
been crystallized as a monomeric form [21,22].
In order to understand the molecular bases for the regula-
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tory mechanisms of PTP activity and roles of D2 we have
examined molecular interactions in the cytoplasmic region of
CD45 using yeast the two-hybrid system. Consequently, we
have found a speci¢c and predominant interaction between
the spacer (Sp) region and D2, which might occur intramolec-
ularly. In addition, it appears that the membrane proximal
region itself does not directly interact with any of cytoplasmic
domains but rather participates in stabilizing the Sp-D2 inter-
action.
2. Materials and methods
2.1. Plasmid construction and mutagenesis
The cytoplasmic region of human CD45 was dissected into ¢ve
distinct domains, membrane proximal (Mp, amino acid residues
5751^647), PTP-D1 (D1, 647^897), Sp, 897^937), PTP-D2 (D2, 937^
1211) and carboxyl-terminal (Ct, 1211^1281) domains (Fig. 1). This
conventional delineation has been evolved from delineation of core
phosphatase domains (D1 and D2) based on the sequence conserva-
tion analysis, and thereby denotes £anking regions as Mp, Sp and Ct
[15,16]. The cDNA segments corresponding to each domain were
ampli¢ed from a human thymus cDNA library (Clontech) by poly-
merase chain reaction (PCR) and cloned into pCR-Blunt (Invitrogen).
The full-length cytoplasmic region was constructed by combining D1
and D2 regions at the BsmBI site in the Sp region. After sequence
veri¢cation, each DNA segment was recloned into pACT2 and pAS2-
1 (Clontech). In all cases both combination of construction with
pACT2 and pAS2-1 were examined for two-hybrid interaction. Ex-
pression of each fusion protein in yeast cells was con¢rmed by West-
ern blotting using antibodies against either the Gal4 transactivation
domain or DNA-binding domain (Clontech). Random mutagenesis of
the Sp region was conducted by a PCR-mediated method using Taq
DNA polymerase (Takara) [23].
2.2. Two-hybrid assay for protein-protein interaction
A yeast strain YRG-2 (Stratagene Cloning Systems) was made
competent for DNA transfection using YEASTMAKER yeast trans-
formation system (Clontech), and transformed with 1 Wg of each
plasmid DNA. Transformants were selected at 30‡C using appropriate
auxotrophic markers on SD-medium agar plates (Bio 101). The
growth of transformants on His3 plates was investigated as a conven-
tional indication of interactions in the two-hybrid system. 3-Amino-
1,2,4-triazole (3-AT), a competitive inhibitor of the yeast His3 protein,
was added to the His3 plates with various concentration (0.1^10 mM)
to compare the relative strength of interactions. L-Galactosidase ac-
tivity in each of the transformants was measured according to the
published method using either o-nitrophenyl L-D-galactopyranoside
(ONPG) or chlorophenolred-L-D-galactopyranoside (CPRG) as a sub-
strate [24]. Speci¢c activity and relative activity are the average of
several independent assays using at least four independent transform-
ants.
2.3. Other materials and methods
Standard PCR reactions were performed under the error-prone
condition using Pfu DNA polymerase (Stratagene Cloning Systems).
DNA sequences were determined on an ABI 310 DNA sequencer
using PCR-mediated dye terminator methods. Restriction enzymes
and ligase were purchased from Toyobo. Other reagents including
3-AT, ONPG and CPRG were purchased from Sigma and of the
highest grade available.
3. Results
3.1. Interaction between D1 and D2
In order to examine interaction between the two major
domains, D1 and D2, we made four constructs : D1 alone,
D1 connected with Mp and Sp, D2 alone and D2 connected
with Sp and Ct (Fig. 1). As shown in Fig. 2 (left), Mp-D1-Sp
interacted with both Sp-D2-Ct and D2 alone. These interac-
tions were con¢rmed and semi-quanti¢ed by the L-galactosi-
dase activity (Table 1). In both assays Mp-D1-Sp interacted
more strongly with D2 alone than Sp-D2-Ct. In contrast, no
signi¢cant interaction was observed between D1 alone and Sp-
D2-Ct or D2 (Fig. 2 and Table 1). These results suggest that
Mp and/or Sp are essential for interaction of Mp-D1-Sp with
D2.
No signi¢cant interactions were observed in homomeric
combinations between the longer and shorter versions of D1
Fig. 1. Map of DNA segments carried by plasmids for the yeast
two-hybrid system. The cytoplasmic region of human CD45 was dis-
sected into ¢ve distinct domains, membrane proximal (Mp), PTP-
D1 (D1), spacer (Sp), PTP-D2 (D2) and carboxyl-terminal (Ct) do-
mains. Horizontal boxes represent domains carried by each plasmid.
Numbers indicate the amino acid residue at the boundary of each
domain.
Table 1
L-Galactosidase reporter quanti¢cation of protein-protein interac-
tions between distinct domains of CD45
pAS2-1 pACT2 L-Galactosidasea
Vector vector 0.03
p53 SV40-LT 11.53
Mp-D1-Sp Sp-D2-Ct 0.52
Mp-D1-Sp D2 4.73
D1 Sp-D2-Ct 0.00
D1 D2 0.03
Mp-D1-Sp Mp-D1-Sp 0.09
D1 D1 0.06
D1 Mp-D1-Sp 0.05
Sp-D2-Ct Sp-D2-Ct 0.01
D2 D2 0.03
D2 Sp-D2-Ct 0.04
Mp-D1 Sp-D2-Ct 0.07
Mp-D1 D2 0.03
D1-Sp Sp-D2-Ct 0.04
D1-Sp D2 0.40
Mp Sp-D2-Ct 0.03
Mp D2 0.03
Sp Sp-D2-Ct 0.01
Sp D2 0.85
Mp Mp-D1-Sp 0.03
Mp D1 0.04
Sp Mp-D1-Sp 0.06
Sp D1 0.06
Full-length Full-length 0.02
D1-Sp-D2 D1-Sp-D2 0.03
aValues for L-galactosidase represent the speci¢c activity calculated
as described [24].
1 The number of amino acid residues of human CD45 was counted
from the amino-terminus of the mature protein devoid of a signal
sequence.
FEBS 23345 10-2-00
K. Hayami-Noumi et al./FEBS Letters 468 (2000) 68^72 69
and D2 (Fig. 2 (left) and Table 1). However, weak interac-
tions between Mp-D1-Sp and Mp-D1-Sp, D1 and D1, and
Mp-D1-Sp and D1 were detected in growth reporter assay
under the less stringent condition of only 0.1 mM 3-AT
(data not shown).
3.2. Interaction between Sp and D2
Since Mp and/or Sp appear to be involved in interaction
with D2 we made truncated constructs that carried either Mp
or Sp with D1 (Fig. 1). As shown in Fig. 2 (right) and Table 1,
D1-Sp interacted with D2 but Mp-D1 did not. Thus, Sp is
assumed to predominantly participate in interaction with D2.
It should be noted that D1-Sp did not interact with Sp-D2-Ct
as predicted from the previous results indicating that D1-Sp
was less competent to interact with D2 than Mp-D1-Sp. We
have further truncated the carboxyl-half of Sp from D1-Sp,
which resulted in loss of interaction with D2 (data not
shown).
Finally, we expressed either Mp or Sp alone to examine if
Sp directly interacted with D2. As demonstrated in Fig. 2
(right), Sp alone could directly interact with D2 although it
did not interact with Sp-D2-Ct, while Mp alone interacted
with neither D2 nor Sp-D2-Ct. Activity in the L-galactosidase
assay was consistent with these observations (Table 1). Inter-
estingly, neither Mp nor Sp interacted with D1 or Mp-D1-Sp
at all (Table 1).
3.3. E¡ect of point mutation on interaction between Sp and D2
To further validate direct interaction between Sp and D2
and to identify the Sp amino acid residues involved in the
interaction, we have randomly and site-directedly introduced
single amino acid replacement in Sp (Fig. 3). Of seventeen
single mutations created, which correspond to about half of
the residues in Sp, nine mutations resulted in dramatic de-
crease in Sp interaction with D2 (Table 2). The same results
were obtained when these mutations were re-introduced in
Mp-D1-Sp (data not shown). Interestingly, seven negative
mutations were clustered in a single stretch of the primary
structure (Fig. 3). These results indicate that the interaction
between Sp and D2 is speci¢c.
3.4. Dimerization of CD45 cytoplasmic region
Given the strong interaction between Sp and D2, we exam-
ined dimerization of the full-length cytoplasmic region of
CD45. The full-length cytoplasmic region and its truncated
variant D1-Sp-D2 were cloned into pACT2 and pAS2-1
(Fig. 1). Neither full-length nor D1-Sp-D2 showed homomeric
interaction in yeast two-hybrid assays (Table 1). However, the
truncated variant D1-Sp-D2 showed a weak tendency to form
a homodimer under less stringent conditions, as observed with
the homomeric combinations of D1 and Mp-D1-Sp (data not
shown).
4. Discussion
Although the tyrosine phosphatase activity of CD45 is be-
Fig. 2. Growth reporter assay for yeast two-hybrid interactions be-
tween distinct domains of CD45. Each pACT2 (horizontal lanes)
and pAS2-1 (vertical lanes) construct was cotransfected into a yeast
strain YRG-2. Transformants were streaked on SD plates devoid of
histidine and incubated at 30‡C for 4 days. The plates contained 10
mM 3-AT. The negative and positive controls for the two-hybrid in-
teraction correspond to cotransfections of pACT2 and pAS2-1, and
SV40-LT and p53, respectively.
Table 2
E¡ect of mutations on Sp-D2 interaction
Mutation in Sp Relative activitya
Wild 1.00
S898C 0.80
E899Q 0.06
Y903F 0.63
L904P 0.08
M907V 0.82
K908R 0.59
E915G 0.58
S917P 0.12
E920K 0.15
A921T 0.15
F923L 0.05
R925G 0.12
L926P 0.03
P927S 0.09
R933W 1.02
T934A 0.70
H936N 0.78
aRelative activity was calculated from the speci¢c activity of L-ga-
lactosidase.
Fig. 3. Positive and negative mutations in the Sp region for interac-
tion with D2. Possible secondary structure of the Sp region was de-
picted based on Chou and Fasman prediction [27]. Mutations which
abrogated the interaction between Sp and D2 are underlined.
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lieved to be a key factor in T-cell signal transduction, the
mechanisms of phosphatase regulation are not yet fully under-
stood. In the present paper, we demonstrated intra- and in-
termolecular interactions between distinct cytoplasmic do-
mains of human CD45. Our results clearly indicate that the
Sp region between two tandem phosphatase domains (D1 and
D2) interact with D2. The interaction appears to be speci¢c
since no interaction of Sp with D1 was observed in spite of
signi¢cant sequence homology between D1 and D2. The es-
sential role of Sp identi¢ed in this study is consistent with the
observation that deletion of Sp from the murine CD45 cyto-
plasmic region abolishes PTP activity in vitro [25]. In addi-
tion, recent publication of the crystal structure of LAR D1-
D2 described the close proximity of Sp to D2 in a single
molecule [22]. Recently Felberg and Johnson reported binding
of D1 to D2 in in vitro binding assays [17], however, their D1
protein contained both the membrane proximal (Mp) region
and Sp. Therefore, the binding of D1 to D2 observed in pre-
vious studies may likely be mediated by Sp embedded in the
D1 protein.
We have further identi¢ed a series of point mutations in the
carboxyl-terminal half of Sp, which abolish the interaction
between Sp and D2. The Sp region is predicted to form a
hairpin structure having a L-turn in the middle of the struc-
ture (Fig. 3 and [22]). Interestingly, most of negative muta-
tions are clustered in one side of the hairpin structure.
Although the negative interaction between mutant Sp and
D2 might be due to a gross conformational change of Sp,
the carboxyl-terminal half of Sp is assumed to exhibit direct
contact with D2 as a distinct domain since several di¡erent
mutations in a restricted region abrogated the interaction.
Supporting this notion, limited but signi¢cant sequence ho-
mology was observed only in the carboxyl-terminal region
of Sp while overall conservation among Sp regions of various
two-domain PTPs was low [2]. Presently we do not know
about the particular domains and residues in D2 responsible
for binding to Sp. In this context, it may be worth noting that
truncation of carboxyl-terminal 23 residues of D2 or a point
mutation in the relevant region abolished PTP activity of
murine CD45 [16,25]. Thus, the carboxyl-terminal region of
D2 may be a possible target for interaction with Sp. Indeed,
the closest proximity is observed between the Sp and two
K-helix structures in the carboxyl-terminus of D2 in the crys-
tal structure of LAR [22].
Previously, many people anticipated that the CD45 cyto-
plasmic region might have a tendency to homodimerize
through a direct interaction between Mp and D1. This spec-
ulation has evolved from a small number of indirect indica-
tions: (i) PTPK, which is structurally similar to CD45, crys-
tallizes to form a dimer in which the two molecules interact
via mutual protrusion of the membrane proximal wedge struc-
ture (Mp) to the catalytic cleft of the opposite molecule [20],
(ii) an Mp mutation modulates ligand induced signal trans-
mission elicited by a chimera protein consisting of EGF-R
and CD45 [26]. However, in the present study we observed
neither interaction between Mp alone nor Mp-D1 and D1.
Although we can not exclude the possibility that Mp and
D1 are unstable or incorrectly folded when expressed solely,
these results may suggest that either di¡erent mechanisms
operate in regulation of the catalytic activities of CD45 and
PTPK, or Mp simply a¡ect the catalytic activity of D1
through intra- and/or intermolecular interactions between Sp
and D2. Nonetheless, Mp appear to support and/or stabilize
the interaction between Sp and D2 since the interaction be-
tween Sp or D1-Sp and D2 was much weaker than that be-
tween Mp-D1-Sp and D2. Alternatively, Mp may stabilize the
conformation of D1 (and D1-Sp) to interact with D2 as sug-
gested in the LAR crystal structure [22]. Consistent with this
indication, deletion of Mp from the murine CD45 cytoplasmic
region results in the loss of PTP activity in vitro [16].
Finally, we observed that Sp could interact only with D2
alone, not with Sp-D2-Ct. This outcome may indicate that the
Sp region in Sp-D2-Ct intramolecularly interacts with D2,
thereby preventing intermolecular interaction between Sp
and Sp-D2-Ct. Taken together, we would speculate that the
cytoplasmic region of CD45 may exist primarily as a mono-
mer. This idea is supported by the observations that active
CD45 D1-D2 enzyme exists as a monomer in vitro [17] and
LAR D1-D2 crystallized as a monomer [22]. The intramolec-
ular folding via interaction between Sp and D2 may encour-
age this active state. In certain cases such as ligand binding or
phosphorylation, dimerization may be induced concomitantly
with release of the intramolecular folding, in which case the
phosphatase activity is negatively regulated via intermolecular
interaction between Mp and the catalytic center in D1.
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